Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Blood Retrieve available abstracts of 324 articles: HTML format

Single Articles

June 2025
1. CHEN C, Xu J, Sussman JH, Vincent T, et al
   Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome.
   Blood. 2025;145:2685-2700.
   PubMed     Abstract available
   
   
   
2. KATER AP, Harrup R, Kipps TJ, Eichhorst B, et al
   The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
   Blood. 2025;145:2733-2745.
   PubMed     Abstract available
   
   
   
3. WIERDA WG, Eichhorst BF, Hallek MJ
   Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia.
   Blood. 2025 Jun 2:blood.2025028570. doi: 10.1182/blood.2025028570.
   PubMed     Abstract available
   
   
   May 2025
4. LU J, Xue SL, Wang Y, He XF, et al
   Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML.
   Blood. 2025;145:2645-2655.
   PubMed     Abstract available
   
   
   
5. EGAN G, Tasian SK
   Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements.
   Blood. 2025;145:2574-2586.
   PubMed     Abstract available
   
   
   
6. ESCHERICH CS, Li Z, Barnett KR, Li Y, et al
   Differentiation-dependent EBF1 Activity Determines CD22 Transcription and Leukemia Sensitivity to Inotuzumab Ozogamicin.
   Blood. 2025 May 28:blood.2024028215. doi: 10.1182/blood.2024028215.
   PubMed     Abstract available
   
   
   
7. MAYDAY MY, Biancon G, Wei M, Ramirez C, et al
   RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation.
   Blood. 2025 May 28:blood.2024027712. doi: 10.1182/blood.2024027712.
   PubMed     Abstract available
   
   
   
8. JUM'AH H, Viswanatha D
   Classic hairy cell leukemia and concomitant smoldering myeloma.
   Blood. 2025;145:2533.
   PubMed    
   
   
   
9. BASSAN R, Chiaretti S, Della Starza I, Santoro A, et al
   Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study.
   Blood. 2025;145:2447-2459.
   PubMed     Abstract available
   
   
   
10. YOSHIMITSU M, Choi I, Kusumoto S, Shimokawa M, et al
    A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma.
    Blood. 2025 May 15:blood.2024027902. doi: 10.1182/blood.2024027902.
    PubMed     Abstract available
    
    
    
11. WANG X, Yi H
    Adult T-cell leukemia/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder.
    Blood. 2025;145:2396.
    PubMed    
    
    
    
12. SAORIN A, Dehler A, Galvan B, Steffen FD, et al
    Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia.
    Blood. 2025 May 13:blood.2025028938. doi: 10.1182/blood.2025028938.
    PubMed     Abstract available
    
    
    
13. ALDOSS I, Clark MC, Forman SJ
    How I Treat: Revisiting the myth of second remission in acute lymphoblastic leukemia in the era of immunotherapy.
    Blood. 2025 May 12:blood.2024027267. doi: 10.1182/blood.2024027267.
    PubMed     Abstract available
    
    
    
14. HOURIGAN CS
    From prognostication to precision in acute myeloid leukemia.
    Blood. 2025;145:2105-2106.
    PubMed    
    
    
    
15. 
    Luskin MR, Murakami MA, Keating J, et al. Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025;145(6):577-589.
    Blood. 2025;145:2231.
    PubMed    
    
    
    
16. LEVIS MJ, Hamadani M, Logan BR, Jones RJ, et al
    Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
    Blood. 2025;145:2138-2148.
    PubMed     Abstract available
    
    
    
17. GOOPTU M, Murdock HM, Soiffer RJ
    How I treat AML relapse after allogeneic HSCT.
    Blood. 2025;145:2128-2137.
    PubMed     Abstract available
    
    
    
18. TEFFERI A, Fathima S, Abdelmagid M, Alsugair A, et al
    BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia.
    Blood. 2025 May 7:blood.2024027170. doi: 10.1182/blood.2024027170.
    PubMed     Abstract available
    
    
    
19. ARELLANO ML, Thirman MJ, DiPersio JF, Heiblig M, et al
    Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
    Blood. 2025 May 7:blood.2025028357. doi: 10.1182/blood.2025028357.
    PubMed     Abstract available
    
    
    
20. BULLINGER L
    Mixed-phenotype acute leukemia revisited: omics lead the way.
    Blood. 2025;145:1969-1971.
    PubMed    
    
    
    April 2025
21. MCMAHON CM
    Beyond conVENtional 7+3 in acute myeloid leukemia.
    Blood. 2025;145:1831-1832.
    PubMed    
    
    
    
22. GARCIAZ S
    STINGing leukemia stem cells through PSTK inhibition.
    Blood. 2025;145:1833-1835.
    PubMed    
    
    
    
23. ZHANG W, Cai J, Wang X, Ma Y, et al
    Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL.
    Blood. 2025;145:1890-1902.
    PubMed     Abstract available
    
    
    
24. PODVIN B, Hardeman A
    Early T-precursor acute lymphoblastic leukemia with mature plasmacytoid dendritic cell proliferation.
    Blood. 2025;145:1827.
    PubMed    
    
    
    
25. CHAKRABORTY SR, Karrs JX
    A rare case of nodal hairy cell leukemia exhibiting characteristic morphological and immunohistochemical features.
    Blood. 2025;145:1826.
    PubMed    
    
    
    
26. DE KESEL J, Fijalkowski I, Pieters T, Borin C, et al
    HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia.
    Blood. 2025 Apr 15:blood.2024026848. doi: 10.1182/blood.2024026848.
    PubMed     Abstract available
    
    
    
27. DAVIDS MS, Kenderian SS, Flinn IW, Hill BT, et al
    ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Blood. 2025 Apr 10:blood.2024027460. doi: 10.1182/blood.2024027460.
    PubMed     Abstract available
    
    
    
28. TURHAN AG
    SMAC mimetics in action in chronic myeloid leukemia.
    Blood. 2025;145:1596-1597.
    PubMed    
    
    
    
29. 
    Zhu H-H, Hu J, Lo-Coco F, Jin J. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood. 2019;134(7):597-605.
    Blood. 2025;145:1703-1705.
    PubMed    
    
    
    
30. SILBERT SK, Rankin AW, Hoang CN, Semchenkova A, et al
    Project EVOLVE: An international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.
    Blood. 2025 Apr 7:blood.2024026655. doi: 10.1182/blood.2024026655.
    PubMed     Abstract available
    
    
    
31. DOMBRET H
    Introduction to a review series on acute lymphoblastic leukemia.
    Blood. 2025;145:1439.
    PubMed    
    
    
    
32. RAMPOTAS A, Roddie C
    The present and future of CAR T-cell therapy for adult B-cell ALL.
    Blood. 2025;145:1485-1497.
    PubMed     Abstract available
    
    
    March 2025
33. BAKHSHI TJ, Pina-Oviedo S
    Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Blood. 2025;145:1437.
    PubMed    
    
    
    
34. CALO-PEREZ A, Martinez-Fernandez R
    Atypical chronic myeloid leukemia: from cytology to molecular characterization.
    Blood. 2025;145:1438.
    PubMed    
    
    
    
35. ROTHFUSS C, Baumann T, Donakonda S, Brauchle B, et al
    Two-layered immune escape in AML is overcome by Fcgamma receptor activation and inhibition of PGE2 signaling in NK cells.
    Blood. 2025;145:1395-1406.
    PubMed     Abstract available
    
    
    
36. HAN Q, Gu Y, Xiang H, Zhang L, et al
    Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL.
    Blood. 2025;145:1407-1421.
    PubMed     Abstract available
    
    
    
37. CHEN J, Suttorp M, Hijiya N
    How I treat chronic myeloid leukemia in children and adolescents.
    Blood. 2025 Mar 25:blood.2024026514. doi: 10.1182/blood.2024026514.
    PubMed     Abstract available
    
    
    
38. KOTROVA M, Proske C, Darzentas N, Laqua A, et al
    NGS-based IG/TR rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation.
    Blood. 2025 Mar 25:blood.2024027175. doi: 10.1182/blood.2024027175.
    PubMed     Abstract available
    
    
    
39. LUGER SM
    Introduction to a How I Treat series on acute myeloid leukemia.
    Blood. 2025;145:1227-1228.
    PubMed    
    
    
    
40. FURSTENAU M, Robrecht S, Schneider C, Tausch E, et al
    MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
    Blood. 2025;145:1282-1292.
    PubMed     Abstract available
    
    
    
41. WEI AH, Loo S, Daver N
    How I treat patients with AML using azacitidine and venetoclax.
    Blood. 2025;145:1237-1250.
    PubMed     Abstract available
    
    
    
42. LUO Q, Fortune AL, Lane AA
    PI3Kgamma in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target.
    Blood. 2025 Mar 19:blood.2024027376. doi: 10.1182/blood.2024027376.
    PubMed     Abstract available
    
    
    
43. XU J, Sussman JH, Yang A, Yoshimura S, et al
    STAT1-mediated interferon signatures associate with preclinical JAK-inhibitor sensitivity in T-cell acute lymphoblastic leukemia.
    Blood. 2025 Mar 18:blood.2025028566. doi: 10.1182/blood.2025028566.
    PubMed     Abstract available
    
    
    
44. DALGETTY M, Cortes J
    Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?
    Blood. 2025 Mar 18:blood.2024027944. doi: 10.1182/blood.2024027944.
    PubMed     Abstract available
    
    
    
45. FALGAS A, Lazaro-Gorines R, Zanetti SR, Rubio-Perez L, et al
    A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.
    Blood. 2025 Mar 16:blood.2024025440. doi: 10.1182/blood.2024025440.
    PubMed     Abstract available
    
    
    
46. WANG WJ, Loghavi S
    Acute myeloid leukemia with RUNX1::CBFA2T3 fusion.
    Blood. 2025;145:1226.
    PubMed    
    
    
    
47. WULIJI N, Jones SMW, Gooley TA, Gerds AT, et al
    Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
    Blood. 2025 Mar 11:blood.2024027543. doi: 10.1182/blood.2024027543.
    PubMed     Abstract available
    
    
    
48. TAM CS, Balendran S, Blombery P
    Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors.
    Blood. 2025;145:1005-1009.
    PubMed     Abstract available
    
    
    February 2025
49. ZEIDNER JF, Sallman DA, Recher C, Daver NG, et al
    Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
    Blood. 2025 Feb 26:blood.2024027408. doi: 10.1182/blood.2024027408.
    PubMed     Abstract available
    
    
    
50. TAMIRO F, Padovano C, De Santis E, Di Iasio S, et al
    NOTCH1 dimeric signaling is essential for T-cell leukemogenesis and leukemia maintenance.
    Blood. 2025 Feb 26:blood.2024027020. doi: 10.1182/blood.2024027020.
    PubMed     Abstract available
    
    
    
51. CONDOLUCI A, Romano I, Dietrich D, Pini K, et al
    Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17.
    Blood. 2025 Feb 26:blood.2024026879. doi: 10.1182/blood.2024026879.
    PubMed     Abstract available
    
    
    
52. ALLEN B, Bottomly D, Kohnke T, Wang A, et al
    A CEBPB/IL-1beta/TNF-alpha Feedback Loop Drives Drug Resistance to Venetoclax and MDM2 Inhibitors in Monocytic Leukemia.
    Blood. 2025 Feb 26:blood.2024028239. doi: 10.1182/blood.2024028239.
    PubMed     Abstract available
    
    
    
53. LINDER A, Nixdorf D, Kuhl N, Piseddu I, et al
    STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia.
    Blood. 2025 Feb 26:blood.2024026934. doi: 10.1182/blood.2024026934.
    PubMed     Abstract available
    
    
    
54. AL JABRI M, Chang H
    Blastoid variant of double-hit lymphoma masquerading as acute lymphoblastic leukemia.
    Blood. 2025;145:897.
    PubMed    
    
    
    
55. PARISI X, Loghavi S
    Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle of phenotype versus genotype.
    Blood. 2025;145:784.
    PubMed    
    
    
    
56. SHAH V, Giotopoulos G, Osaki H, Meyerhofer M, et al
    Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation.
    Blood. 2025;145:748-764.
    PubMed     Abstract available
    
    
    
57. SILVA HJ, Martin G, Birocchi F, Wehrli M, et al
    CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML.
    Blood. 2025;145:720-731.
    PubMed     Abstract available
    
    
    
58. MANTZARIS I, Goldfinger M, Uriel M, Shastri A, et al
    Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study.
    Blood. 2025 Feb 7:blood.2024026700. doi: 10.1182/blood.2024026700.
    PubMed     Abstract available
    
    
    
59. SHEN Q, Hu S
    Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements.
    Blood. 2025;145:652.
    PubMed    
    
    
    
60. FISKUS W, Mill CP, Bose P, Masarova L, et al
    Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.
    Blood. 2025;145:612-624.
    PubMed     Abstract available
    
    
    
61. HE L, Zhao T, Leong WZ, Sharda A, et al
    PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells.
    Blood. 2025 Feb 5:blood.2024026040. doi: 10.1182/blood.2024026040.
    PubMed     Abstract available
    
    
    January 2025
62. LYAPICHEV KA, Behdad A
    c-MYC stain as a potential minimal residual disease marker for acute myeloid leukemia with NPM1 mutation.
    Blood. 2025;145:547.
    PubMed    
    
    
    
63. POHLY MF, Putzker K, Scheinost S, Ben Taarit L, et al
    IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput drug screening.
    Blood. 2025 Jan 27:blood.2024027171. doi: 10.1182/blood.2024027171.
    PubMed     Abstract available
    
    
    
64. ABEDIN SM, Uy GL, Michaelis LC
    The Fit Older Adult with Acute Myeloid Leukemia: Clinical Challenges to Providing Evidence-Based Frontline Treatment.
    Blood. 2025 Jan 24:blood.2024026004. doi: 10.1182/blood.2024026004.
    PubMed     Abstract available
    
    
    
65. CHAPAPRIETA V, Maiques-Diaz A, Nadeu F, Clot G, et al
    Dual Biological Role and Clinical Impact of De Novo Chromatin Activation in Chronic Lymphocytic Leukemia.
    Blood. 2025 Jan 22:blood.2024025396. doi: 10.1182/blood.2024025396.
    PubMed     Abstract available
    
    
    
66. ALIKARAMI F, Xie HM, Riedel SS, Goodrow H, et al
    GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia.
    Blood. 2025 Jan 22:blood.2024025761. doi: 10.1182/blood.2024025761.
    PubMed     Abstract available
    
    
    
67. LYU J, Liu Y, Liu N, Vu H, et al
    CD44-Mediated Metabolic Rewiring is A Targetable Dependency of IDH-Mutant Leukemia.
    Blood. 2025 Jan 22:blood.2024027207. doi: 10.1182/blood.2024027207.
    PubMed     Abstract available
    
    
    
68. SCHAFER HACKENHAAR F, Refhagen N, Hagleitner MM, van Leeuwen FN, et al
    CpG island methylator phenotype classification improves risk assessment in pediatric T-cell Acute Lymphoblastic Leukemia.
    Blood. 2025 Jan 22:blood.2024026027. doi: 10.1182/blood.2024026027.
    PubMed     Abstract available
    
    
    
69. ARAUJO JL, Wagenblast E, Voisin V, McLeod J, et al
    FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells.
    Blood. 2025 Jan 22:blood.2024025886. doi: 10.1182/blood.2024025886.
    PubMed     Abstract available
    
    
    
70. GALERA P, Dilip D, Derkach A, Chan A, et al
    Defining 2 Biologically and Clinically Distinct Groups in Acute Leukemia with a Mixed Phenotype.
    Blood. 2025 Jan 15:blood.2024026273. doi: 10.1182/blood.2024026273.
    PubMed     Abstract available
    
    
    
71. RONNACKER J, Grau M, Klasmeier M, Klesse C, et al
    Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia.
    Blood. 2025 Jan 15:blood.2024026886. doi: 10.1182/blood.2024026886.
    PubMed     Abstract available
    
    
    
72. NYGREN PJ, Bouhlal JOV, Jokinen E, Forsten S, et al
    High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia.
    Blood. 2025 Jan 10:blood.2024025286. doi: 10.1182/blood.2024025286.
    PubMed     Abstract available
    
    
    
73. PURVIS K, Zhou Y, Karol SE, Rubnitz JE, et al
    Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.
    Blood. 2025;145:190-201.
    PubMed     Abstract available
    
    
    
74. DING YY, Sussman JH, Madden K, Loftus JP, et al
    Targeting Senescent Stemlike Subpopulations in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
    Blood. 2025 Jan 7:blood.2024026482. doi: 10.1182/blood.2024026482.
    PubMed     Abstract available
    
    
    
75. BASKAR S, Peng H, Gaglione EM, Carstens EJ, et al
    Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.
    Blood. 2025 Jan 7:blood.2024024846. doi: 10.1182/blood.2024024846.
    PubMed     Abstract available
    
    
    
76. DOMBRET H
    Introduction to a How I Treat series on acute lymphoblastic leukemia.
    Blood. 2025;145:1-2.
    PubMed    
    
    
    
77. CHIARETTI S, Foa R
    How I treat adult Ph+ ALL.
    Blood. 2025;145:11-19.
    PubMed     Abstract available
    
    
    
78. LAMBLE AJ, Kovach AE, Shah NN
    How I treat postimmunotherapy relapsed B-ALL.
    Blood. 2025;145:64-74.
    PubMed     Abstract available
    
    
    December 2024
79. PASSET M, Kim R, Clappier E
    Genetic subtypes of B-cell acute lymphoblastic leukemia in adults.
    Blood. 2024 Dec 30:blood.2023022919. doi: 10.1182/blood.2023022919.
    PubMed     Abstract available
    
    
    
80. CRUZ-RODRIGUEZ N, Deininger MW
    Novel Treatment Strategies for Chronic Myeloid Leukemia.
    Blood. 2024 Dec 27:blood.2024026312. doi: 10.1182/blood.2024026312.
    PubMed     Abstract available
    
    
    
81. ESCHERICH CS, Moriyama T, Li Z, Hsiao Y, et al
    DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Dec 27:blood.2024026085. doi: 10.1182/blood.2024026085.
    PubMed     Abstract available
    
    
    
82. MILLMAN SE, Chaves-Perez A, Janaki-Raman S, Ho YJ, et al
    alpha-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia.
    Blood. 2024 Dec 27:blood.2024025245. doi: 10.1182/blood.2024025245.
    PubMed     Abstract available
    
    
    
83. NAHARRO EF, Linden MA
    Auer rod-like inclusions in B-cell lymphoma mimicking therapy-related acute myeloid leukemia.
    Blood. 2024;144:2793.
    PubMed    
    
    
    
84. LACHOWIEZ CA, Ravikumar VI, Othman J, O'Nions J, et al
    Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.
    Blood. 2024;144:2788-2792.
    PubMed     Abstract available
    
    
    
85. BROWN JR, Eichhorst B, Lamanna N, O'Brien SM, et al
    Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.
    Blood. 2024;144:2706-2717.
    PubMed     Abstract available
    
    
    
86. HULS GA, Woolthuis CM, Schuringa JJ
    Menin inhibitors in the treatment of acute myeloid leukemia.
    Blood. 2024 Dec 24:blood.2024026232. doi: 10.1182/blood.2024026232.
    PubMed     Abstract available
    
    
    
87. ARONS E, Tai CH, Suraj J, Liu Y, et al
    Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia.
    Blood. 2024 Dec 24:blood.2024026894. doi: 10.1182/blood.2024026894.
    PubMed     Abstract available
    
    
    
88. CUI B, Ai L, Lei M, Duan Y, et al
    Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia.
    Blood. 2024 Dec 11:blood.2024025618. doi: 10.1182/blood.2024025618.
    PubMed     Abstract available
    
    
    
89. BOUDIA F, Baille M, Babin L, Aid Z, et al
    Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of pediatric leukemia initiation.
    Blood. 2024 Dec 10:blood.2024024505. doi: 10.1182/blood.2024024505.
    PubMed     Abstract available
    
    
    
90. HAUBNER S, Subklewe M, Sadelain M
    Honing CAR T cells to tackle acute myeloid leukemia.
    Blood. 2024 Dec 4:blood.2024024063. doi: 10.1182/blood.2024024063.
    PubMed     Abstract available
    
    
    November 2024
91. GOLDFINGER M, Mantzaris I, Shastri A, Saunthararajah Y, et al
    A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
    Blood. 2024;144:2360-2363.
    PubMed     Abstract available
    
    
    
92. DOHNER H, DiNardo CD, Appelbaum FR, Craddock C, et al
    Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
    Blood. 2024;144:2169-2173.
    PubMed     Abstract available
    
    
    
93. DOHNER H, Pratz KW, DiNardo CD, Wei AH, et al
    Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.
    Blood. 2024;144:2211-2222.
    PubMed     Abstract available
    
    
    
94. MA J, Wang Z, Mintzlaff D, Zhang H, et al
    Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Nov 19:blood.2024025277. doi: 10.1182/blood.2024025277.
    PubMed     Abstract available
    
    
    
95. NAIR MS, Silbert SK, Rejeski K, Wilson KA, et al
    Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.
    Blood. 2024 Nov 19:blood.2024025910. doi: 10.1182/blood.2024025910.
    PubMed     Abstract available
    
    
    
96. LU P, Zhang X, Yang J, Li J, et al
    Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia.
    Blood. 2024 Nov 19:blood.2024024861. doi: 10.1182/blood.2024024861.
    PubMed     Abstract available
    
    
    
97. 
    Handa S, Lee J-O, Derkach A, et al. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood. 2022;140(25):2663-2671.
    Blood. 2024;144:2068.
    PubMed    
    
    
    
98. CHEVALIER S, Legrand C
    B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma.
    Blood. 2024;144:2067.
    PubMed    
    
    
    
99. HUNTER AM, Patnaik MM, Itzykson R, Mesa R, et al
    Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
    Blood. 2024;144:1987-1992.
    PubMed     Abstract available
    
    
    
100. LOPEZ-MILLAN B, Rubio-Gayarre A, Vinyoles M, Trincado JL, et al
     NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression.
     Blood. 2024;144:2002-2017.
     PubMed     Abstract available
     
     
     
101. VOSO MT, Guarnera L, Lehmann S, Dohner K, et al
     Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project.
     Blood. 2024 Nov 6:blood.2024026186. doi: 10.1182/blood.2024026186.
     PubMed     Abstract available
     
     
     
102. GUILHOT F, Hehlmann R
     Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia.
     Blood. 2024 Nov 1:blood.2024026311. doi: 10.1182/blood.2024026311.
     PubMed     Abstract available
     
     
     October 2024
103. LUO MX, Tan T, Trussart M, Poch A, et al
     Venetoclax Dose Escalation Rapidly Activates a BAFF/BCL-2 Survival Axis in Chronic Lymphocytic Leukemia.
     Blood. 2024 Oct 29:blood.2024024341. doi: 10.1182/blood.2024024341.
     PubMed     Abstract available
     
     
     
104. WU Q, Chen D
     Near early T-precursor lymphoblastic leukemia with marked flower petal nuclei: blast with unique cyanthiform nucleus.
     Blood. 2024;144:1846.
     PubMed    
     
     
     
105. KIM E, Chen SS, Sivina M, Hwang H, et al
     Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD.
     Blood. 2024 Oct 23:blood.2024025683. doi: 10.1182/blood.2024025683.
     PubMed     Abstract available
     
     
     
106. LIU Y, Bollino DR, Bah OM, Strovel ET, et al
     A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia.
     Blood. 2024 Oct 22:blood.2024024837. doi: 10.1182/blood.2024024837.
     PubMed     Abstract available
     
     
     
107. GOKBUGET N, Steffen B
     How I Treat Older Patients with Ph/BCR-ABL-Negative Acute Lymphoblastic Leukemia.
     Blood. 2024 Oct 11:blood.2023023156. doi: 10.1182/blood.2023023156.
     PubMed     Abstract available
     
     
     
108. KWOK M, Stankovic T
     Targeting therapeutic vulnerabilities in T-PLL.
     Blood. 2024;144:1548-1550.
     PubMed    
     
     
     
109. NIEDER R, Li W
     Constitutive STAT5 activation in precursor B-cell acute lymphoblastic leukemia with P2RY8::CRLF2 fusion.
     Blood. 2024;144:1646.
     PubMed    
     
     
     
110. VON JAN J, Timonen S, Braun T, Jiang Q, et al
     Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses.
     Blood. 2024;144:1595-1610.
     PubMed     Abstract available
     
     
     
111. SIMONIN M, Vasseur L, Lengline E, Lhermitte L, et al
     NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.
     Blood. 2024;144:1570-1580.
     PubMed     Abstract available
     
     
     
112. NEWMAN H, Teachey DT
     A T-ALL order: a new risk classifier for T-ALL.
     Blood. 2024;144:1545-1547.
     PubMed    
     
     
     
113. ROBOZ GJ, Canaani J
     How I use Maintenance Therapy in Acute Myeloid Leukemia.
     Blood. 2024 Oct 7:blood.2024024010. doi: 10.1182/blood.2024024010.
     PubMed     Abstract available
     
     
     
114. LUSKIN MR, Murakami MA, Keating JH, Flamand Y, et al
     Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
     Blood. 2024 Oct 7:blood.2024025800. doi: 10.1182/blood.2024025800.
     PubMed     Abstract available
     
     
     
115. ZHOU X, Chen X, Chen J, Wen L, et al
     Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APL.
     Blood. 2024;144:1471-1485.
     PubMed     Abstract available
     
     
     
116. POLONEN P, Mullighan CG, Teachey DT
     Classification and risk stratification in T-lineage acute lymphoblastic leukemia.
     Blood. 2024 Oct 2:blood.2023022920. doi: 10.1182/blood.2023022920.
     PubMed     Abstract available
     
     
     
117. KYTOLA S, Vanttinen IM, Ruokoranta T, Partanen A, et al
     Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial.
     Blood. 2024 Oct 2:blood.2024024968. doi: 10.1182/blood.2024024968.
     PubMed     Abstract available
     
     
     
118. GREEN SD, Wang ES
     How I Treat: Secondary Acute Myeloid Leukemia.
     Blood. 2024 Oct 2:blood.2024024011. doi: 10.1182/blood.2024024011.
     PubMed     Abstract available
     
     
     September 2024
119. POCOCK R, Mansour MR
     T-ALL and T-LBL: a notch apart.
     Blood. 2024;144:1356-1357.
     PubMed    
     
     
     
120. LI Z, Meng G
     Targeting DUX4-r leukemia via PI3K and CD371.
     Blood. 2024;144:1354-1356.
     PubMed    
     
     
     
121. SHARMAN JP
     Pirtobrutinib combinations in CLL.
     Blood. 2024;144:1351-1352.
     PubMed    
     
     
     
122. THORSSON H, Henningsson R, Puente-Moncada N, Pena-Martinez P, et al
     Single-cell genomics details the maturation block in BCP-ALL and identifies therapeutic vulnerabilities in DUX4-r cases.
     Blood. 2024;144:1399-1411.
     PubMed     Abstract available
     
     
     
123. ROEKER LE, Woyach JA, Cheah CY, Coombs CC, et al
     Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.
     Blood. 2024;144:1374-1386.
     PubMed     Abstract available
     
     
     
124. RAHMAN S, Bloye G, Farah N, Demeulemeester J, et al
     Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.
     Blood. 2024 Sep 24:blood.2024024300. doi: 10.1182/blood.2024024300.
     PubMed     Abstract available
     
     
     
125. JIN Q, Harris E, Myers JA, Mehmood R, et al
     Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemia.
     Blood. 2024 Sep 24:blood.2024024281. doi: 10.1182/blood.2024024281.
     PubMed     Abstract available
     
     
     
126. LOO S, Potter N, Ivey A, O'Nions J Dr, et al
     Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia.
     Blood. 2024 Sep 24:blood.2024026605. doi: 10.1182/blood.2024026605.
     PubMed     Abstract available
     
     
     
127. WANG ES
     Curing APL in Latin America: more than just ATRA.
     Blood. 2024;144:1237-1238.
     PubMed    
     
     
     
128. BONADIES N
     SHERLOCK unmasks fusion-driven leukemias.
     Blood. 2024;144:1241-1243.
     PubMed    
     
     
     
129. VEDULA RS, Karp HQ, Koob J, Lim F, et al
     CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias.
     Blood. 2024;144:1290-1299.
     PubMed     Abstract available
     
     
     
130. PENTER L, Wu CJ
     Therapy response in AML: a tale of two T cells.
     Blood. 2024;144:1134-1136.
     PubMed    
     
     
     
131. KWON MC, Thuring JW, Querolle O, Dai X, et al
     Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
     Blood. 2024;144:1206-1220.
     PubMed     Abstract available
     
     
     
132. WALTER RB, Potter V, Craddock C
     Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old.
     Blood. 2024 Sep 6:blood.2024024247. doi: 10.1182/blood.2024024247.
     PubMed     Abstract available
     
     
     
133. BADAR T, Luger SM, Litzow MR
     Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia.
     Blood. 2024 Sep 5:blood.2023022921. doi: 10.1182/blood.2023022921.
     PubMed     Abstract available
     
     
     
134. SALLMAN DA, Stahl M
     TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?
     Blood. 2024 Sep 5:blood.2024024245. doi: 10.1182/blood.2024024245.
     PubMed     Abstract available
     
     
     
135. FALKENBURG JHF, Heemskerk MHM
     TCR targeting hematopoiesis to cure leukemia.
     Blood. 2024;144:1031-1033.
     PubMed    
     
     
     August 2024
136. SUMMERS RJ, Teachey DT
     SNPing away poor outcomes in T-ALL.
     Blood. 2024;144:924-925.
     PubMed    
     
     
     
137. EADIE LN, Lagonik E, Page EC, Schutz CE, et al
     Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.
     Blood. 2024;144:1022-1026.
     PubMed    
     
     
     
138. BALDUCCI E, Simonin M, Duployez N, Steimle T, et al
     Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL.
     Blood. 2024;144:988-1000.
     PubMed     Abstract available
     
     
     
139. WADHWA A, Chen Y, Hageman L, Angiolillo A, et al
     Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia: A COG-AALL03N1 Report.
     Blood. 2024 Aug 27:blood.2024024455. doi: 10.1182/blood.2024024455.
     PubMed     Abstract available
     
     
     
140. COBALEDA C, Sanchez-Garcia I
     Childhood leukemia prevention within reach.
     Blood. 2024;144:799-800.
     PubMed    
     
     
     
141. INGELFINGER F
     Hijacking T helper cells for AML progression.
     Blood. 2024;144:804-805.
     PubMed    
     
     
     
142. XU Z, Padmore R
     AML, myelodysplasia related, with STAG2 and SRSF2 comutations with myelocyte arrest.
     Blood. 2024;144:918.
     PubMed    
     
     
     
143. BHATLA T, Hogan L MD, Teachey DT, Bautista F, et al
     Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study.
     Blood. 2024 Aug 16:blood.2024024493. doi: 10.1182/blood.2024024493.
     PubMed     Abstract available
     
     
     
144. ZHOU X, Zhang L, Aryal S, Veasey V, et al
     Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia.
     Blood. 2024 Aug 16:blood.2023023644. doi: 10.1182/blood.2023023644.
     PubMed     Abstract available
     
     
     
145. HU Z, Ok CY
     Immature erythroblasts in pleural effusion: an initial presentation of acute erythroid leukemia in a patient with a history of MDS.
     Blood. 2024;144:794.
     PubMed    
     
     
     
146. ITZYKSON R
     NPM1-mutated AML: how many diseases?
     Blood. 2024;144:681-683.
     PubMed    
     
     
     
147. OTHMAN J, Potter N, Ivey A, Tazi Y, et al
     Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
     Blood. 2024;144:714-728.
     PubMed     Abstract available
     
     
     
148. LEYTE-VIDAL A, Garrido Ruiz D, DeFilippis R, Leske IB, et al
     BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
     Blood. 2024;144:639-645.
     PubMed     Abstract available
     
     
     
149. YEUNG DT, Shanmuganathan N, Reynolds J, Branford S, et al
     Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study.
     Blood. 2024 Aug 5:blood.2024024657. doi: 10.1182/blood.2024024657.
     PubMed     Abstract available
     
     
     
150. ARRIETA-BOLANOS E, van der Burg LLJ, Gedde-Dahl T, Robin M, et al
     Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
     Blood. 2024 Aug 5:blood.2024024351. doi: 10.1182/blood.2024024351.
     PubMed     Abstract available
     
     
     
151. 
     Metzeler KH, Herold T, Rothenberg-Turley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686-698.
     Blood. 2024;144:589.
     PubMed    
     
     
     
152. MOSS P
     A tumor suppressor of CLL: all (T-)bets are on.
     Blood. 2024;144:467-469.
     PubMed    
     
     
     
153. COOK JA, Lott L, Perry J, Eckel AM, et al
     Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML.
     Blood. 2024;144:581-585.
     PubMed     Abstract available
     
     
     
154. EFFICACE F, Kicinski M, Coens C, Suciu S, et al
     Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.
     Blood. 2024;144:541-551.
     PubMed     Abstract available
     
     
     July 2024
155. ZHANG X, Liu B, Huang J, Zhang YL, et al
     A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy.
     Blood. 2024 Jul 24:blood.2024024761. doi: 10.1182/blood.2024024761.
     PubMed     Abstract available
     
     
     
156. TE VRUGT M, Wessolowski JS, Randau G, Alfert A, et al
     Pediatric T-cell lymphoblastic lymphoma but not leukemia harbor TRB::NOTCH1 fusions with unfavorable outcome.
     Blood. 2024 Jul 18:blood.2024025307. doi: 10.1182/blood.2024025307.
     PubMed     Abstract available
     
     
     
157. 
     van der Straten L, Stege CAM, Kersting S, et al. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. Blood. 2023;142(13):1131-1142.
     Blood. 2024;144:341.
     PubMed    
     
     
     
158. 
     Melnick AF, Mullin C, Lin K, et al. Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress. Blood. 2023;142(25):2159-2174.
     Blood. 2024;144:342.
     PubMed    
     
     
     
159. RADICH J
     Transplant, MRD, and predicting relapse in AML.
     Blood. 2024;144:245-247.
     PubMed    
     
     
     
160. OPAT S
     Treatment of relapsed CLL "in the BAAG"?
     Blood. 2024;144:243-244.
     PubMed    
     
     
     
161. MUFFLY L, Liang EC, Dolan JG, Pulsipher MA, et al
     How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL.
     Blood. 2024;144:253-261.
     PubMed     Abstract available
     
     
     
162. FURSTENAU M, Giza A, Weiss J, Kleinert F, et al
     Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.
     Blood. 2024;144:272-282.
     PubMed     Abstract available
     
     
     
163. WEI Q, Xu J
     Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.
     Blood. 2024;144:238.
     PubMed    
     
     
     
164. HOURIGAN CS
     How complete must an AML remission be?
     Blood. 2024;144:131-132.
     PubMed    
     
     
     
165. AL-SAWAF O, Robrecht S, Zhang C, Olivieri S, et al
     Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study.
     Blood. 2024 Jul 10:blood.2024024631. doi: 10.1182/blood.2024024631.
     PubMed     Abstract available
     
     
     
166. ISSA GC, Stein EM, DiNardo CDD
     How I Treat: Differentiation Therapy in Acute Myeloid Leukemia.
     Blood. 2024 Jul 8:blood.2024024008. doi: 10.1182/blood.2024024008.
     PubMed     Abstract available
     
     
     
167. SUO S, Zhao D, Li F, Zhang Y, et al
     Homoharringtonine Inhibits the NOTCH/MYC Pathway and Exhibits Anti-Tumor Effects in T-Cell Acute Lymphoblastic Leukemia.
     Blood. 2024 Jul 5:blood.2023023400. doi: 10.1182/blood.2023023400.
     PubMed     Abstract available
     
     
     
168. SRINAGESH HK, Jackson C, Shiraz P, Jeyakumar N, et al
     A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
     Blood. 2024 Jul 5:blood.2024024952. doi: 10.1182/blood.2024024952.
     PubMed     Abstract available
     
     
     
169. LUM SH, Eikema DJ, Piepenbroek B, Wynn R, et al
     Outcome of Hematopoietic Stem Cell Transplantation in 813 Pediatric Patients with Fanconi Anemia.
     Blood. 2024 Jul 5:blood.2023022751. doi: 10.1182/blood.2023022751.
     PubMed     Abstract available
     
     
     
170. QIAN Z, Yu F
     GADD45A: a key tumor suppressor in AML subtypes.
     Blood. 2024;144:6-7.
     PubMed    
     
     
     
171. ZHAO Y, Short NJ, Kantarjian HM, Chang TC, et al
     Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
     Blood. 2024;144:61-73.
     PubMed     Abstract available
     
     
     June 2024
172. RADPOUR R, Simillion C, Wang B, Abbas HA, et al
     IL-9 Secreted by Leukemia Stem Cells Induces Th1-Skewed CD4+ T-Cells, which Promote Their Expansion.
     Blood. 2024 Jun 28:blood.2024024000. doi: 10.1182/blood.2024024000.
     PubMed     Abstract available
     
     
     
173. BIDOT S, Feldman AL
     Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
     Blood. 2024;143:2808.
     PubMed    
     
     
     
174. LENK L, Baccelli I, Laqua A, Heymann J, et al
     The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.
     Blood. 2024;143:2735-2748.
     PubMed     Abstract available
     
     
     
175. LIN HY, Mohammadhosseini M, McClatchy J, Villamor-Paya M, et al
     The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1beta-mediated AML progression.
     Blood. 2024;143:2749-2762.
     PubMed     Abstract available
     
     
     
176. WALCZAK P, Fodil S, Vignal N, Cabannes-Hamy A, et al
     Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1-positive acute lymphoblastic leukemia.
     Blood. 2024 Jun 25:blood.2024024838. doi: 10.1182/blood.2024024838.
     PubMed     Abstract available
     
     
     
177. BARTRAM J, Ancliff P, Vora A
     How I Treat on Infant Acute Lymphoblastic Leukemia.
     Blood. 2024 Jun 21:blood.2023023154. doi: 10.1182/blood.2023023154.
     PubMed     Abstract available
     
     
     
178. 
     Garcia E, Horowitz AM, Franklin K, Mader M, Kaur S. Outcomes of veterans with FMS-like tyrosine kinase 3 mutated (mFLT3) acute myeloid leukemia (AML) treated with novel FLT3 inhibitors (FLT3i) within the Veterans Health Administration (VHA) [abstract]
     Blood. 2024;143:2676.
     PubMed    
     
     
     
179. FORCONI F
     Time for a new prognostic score in CLL?
     Blood. 2024;143:2561-2562.
     PubMed    
     
     
     
180. GAO Q, Harrison CJ
     B-ALL with intrachromosomal amplification of chromosome 21 in a carrier of the Robertsonian translocation rob(14;21)c.
     Blood. 2024;143:2672.
     PubMed    
     
     
     
181. SATO T, Yoshida K, Toki T, Kanezaki R, et al
     Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
     Blood. 2024;143:2627-2643.
     PubMed     Abstract available
     
     
     
182. FARROKHI A, Atre T, Salitra S, Aletaha M, et al
     Early-life infection depletes preleukemic cells in a mouse model of hyperdiploid B-cell acute lymphoblastic leukemia.
     Blood. 2024 Jun 14:blood.2024025038. doi: 10.1182/blood.2024025038.
     PubMed     Abstract available
     
     
     
183. SANZ J, Labopin M, Choi G, Kulagin A, et al
     Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT.
     Blood. 2024;143:2534-2543.
     PubMed     Abstract available
     
     
     
184. MARCHAND T, Lamy de La Chapelle T, Loughran TP
     A modern view of LGL leukemia.
     Blood. 2024 Jun 7:blood.2023021790. doi: 10.1182/blood.2023021790.
     PubMed     Abstract available
     
     
     
185. LUSKIN MR
     Finding the perPh+ect balance in Ph+ ALL.
     Blood. 2024;143:2339-2340.
     PubMed    
     
     
     May 2024
186. KANG YA
     Awakening your innate power to combat AML.
     Blood. 2024;143:2223-2224.
     PubMed    
     
     
     
187. HALL T, Gurbuxani S, Crispino JD
     Malignant progression of preleukemic disorders.
     Blood. 2024;143:2245-2255.
     PubMed     Abstract available
     
     
     
188. ONIDA F, Gagelmann N, Chalandon Y, Kobbe G, et al
     Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
     Blood. 2024;143:2227-2244.
     PubMed     Abstract available
     
     
     
189. KOURY LCA, Kim HT, Undurraga MS, Navarro-Cabrera JR, et al
     Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
     Blood. 2024 May 28:blood.2024023890. doi: 10.1182/blood.2024023890.
     PubMed     Abstract available
     
     
     
190. BRINKMANN BJ, Floerchinger A, Schniederjohann C, Roider T, et al
     CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
     Blood. 2024 May 28:blood.2023022682. doi: 10.1182/blood.2023022682.
     PubMed     Abstract available
     
     
     
191. SAWYER EM, Kraft AS
     SMACing down relapsed T-ALL.
     Blood. 2024;143:2116-2117.
     PubMed    
     
     
     
192. MAZZIOTTA F, Biavati L, Rimando JC, Rutella S, et al
     CD8+ T-cell Differentiation and Dysfunction Inform Treatment Response in Acute Myeloid Leukemia.
     Blood. 2024 May 22:blood.2023021680. doi: 10.1182/blood.2023021680.
     PubMed     Abstract available
     
     
     
193. LEWIS RI, Vom Stein AF, Hallek MJ
     Targeting the tumor microenvironment for treating double refractory chronic lymphocytic leukemia.
     Blood. 2024 May 22:blood.2023022861. doi: 10.1182/blood.2023022861.
     PubMed     Abstract available
     
     
     
194. WOYACH JA, Jones D, Jurczak W, Robak T Prof, et al
     Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
     Blood. 2024 May 16:blood.2023023659. doi: 10.1182/blood.2023023659.
     PubMed     Abstract available
     
     
     
195. 
     MRD and EFS in pediatric T-lymphoblastic lymphoma.
     Blood. 2024;143:2111.
     PubMed    
     
     
     
196. 
     Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
     Blood. 2024;143:2108-2110.
     PubMed    
     
     
     
197. RIBERA JM
     MRD: also for T-lymphoblastic lymphoma.
     Blood. 2024;143:2017-2019.
     PubMed    
     
     
     
198. TAMENI A, Toffalori C, Vago L
     Tricking the Trickster: Precision Medicine Approaches to Counteract Leukemia Immune Escape after Transplant.
     Blood. 2024 May 10:blood.2023019962. doi: 10.1182/blood.2023019962.
     PubMed     Abstract available
     
     
     
199. LE RQ, Przepiorka D, Chen H, Shen YL, et al
     Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia.
     Blood. 2024 May 10:blood.2023023313. doi: 10.1182/blood.2023023313.
     PubMed     Abstract available
     
     
     
200. RECHER C
     Transplant in AML: just follow the NPM1 guide!
     Blood. 2024;143:1881-1882.
     PubMed    
     
     
     
201. SUNG PJ
     PIKing the right target in AML.
     Blood. 2024;143:1884-1885.
     PubMed    
     
     
     
202. OTHMAN J, Potter N, Ivey A, Jovanovic J, et al
     Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
     Blood. 2024;143:1931-1936.
     PubMed     Abstract available
     
     
     
203. GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al
     Management of ALL in adults: 2024 ELN recommendations from a European expert panel.
     Blood. 2024;143:1903-1930.
     PubMed     Abstract available
     
     
     
204. GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al
     Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.
     Blood. 2024;143:1891-1902.
     PubMed     Abstract available
     
     
     April 2024
205. ROESSNER PM, Seufert I, Chapaprieta V, Jayabalan R, et al
     T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.
     Blood. 2024 Apr 29:blood.2023021990. doi: 10.1182/blood.2023021990.
     PubMed     Abstract available
     
     
     
206. KRAKOW EF, Brault M, Summers C, Cunningham TM, et al
     HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
     Blood. 2024 Apr 29:blood.2024024105. doi: 10.1182/blood.2024024105.
     PubMed     Abstract available
     
     
     
207. WIENECKE CP, Heida B, Venturini L, Gabdoulline R, et al
     Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation.
     Blood. 2024 Apr 26:blood.2023022697. doi: 10.1182/blood.2023022697.
     PubMed     Abstract available
     
     
     
208. SUBKLEWE M
     T cells take aim in AML: targeting IDH2.
     Blood. 2024;143:1681-1682.
     PubMed    
     
     
     
209. ABDELBAKY SB, Giacopelli B, Rabe KG, Yamaguchi K, et al
     Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature.
     Blood. 2024;143:1752-1757.
     PubMed     Abstract available
     
     
     
210. TRAN TH, Tasian SK
     How I Treat Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults.
     Blood. 2024 Apr 24:blood.2023023153. doi: 10.1182/blood.2023023153.
     PubMed     Abstract available
     
     
     
211. LAMBLE AJ, Rau RE
     IFN-gamma and CD38 in AML: a T-cell engagement made in heaven?
     Blood. 2024;143:1556-1557.
     PubMed    
     
     
     
212. CUNEO A, Ghia P
     Ibrutinib in CLL: benefit for all?
     Blood. 2024;143:1558-1559.
     PubMed    
     
     
     
213. BUFFET R
     How lipid coating soothes the gut in AML therapy.
     Blood. 2024;143:1559-1561.
     PubMed    
     
     
     
214. RENGA G, Nunzi E, Stincardini C, Pariano M, et al
     CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis.
     Blood. 2024;143:1628-1645.
     PubMed     Abstract available
     
     
     
215. WOYACH JA, Perez Burbano G, Ruppert AS, Miller C, et al
     Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
     Blood. 2024;143:1616-1627.
     PubMed     Abstract available
     
     
     
216. LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
     Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
     Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564.
     PubMed     Abstract available
     
     
     
217. BULLINGER L, Kronke J
     Making AML fly too close to the sun.
     Blood. 2024;143:1438-1439.
     PubMed    
     
     
     
218. BOURGEOIS W, Cutler JA, Aubrey BJ, Wenge DV, et al
     Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
     Blood. 2024;143:1513-1527.
     PubMed     Abstract available
     
     
     
219. KROEZE E, Iaccarino I, Kleisman MM, Mondal M, et al
     Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
     Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938.
     PubMed     Abstract available
     
     
     
220. HASSAN N, Yi H, Malik B, Gaspard-Boulinc LC, et al
     Loss of stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML.
     Blood. 2024 Apr 5:blood.2024024072. doi: 10.1182/blood.2024024072.
     PubMed     Abstract available
     
     
     
221. MARCAIS A
     Targeting PD-L1 to treat ATLL?
     Blood. 2024;143:1320-1322.
     PubMed    
     
     
     
222. MINA A, Greenberg PL, Deeg HJ
     How I reduce and treat posttransplant relapse of MDS.
     Blood. 2024;143:1344-1354.
     PubMed     Abstract available
     
     
     
223. BASTIAN L, Beder T, Barz MJ, Bendig S, et al
     Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
     Blood. 2024;143:1391-1398.
     PubMed     Abstract available
     
     
     March 2024
224. INESS AN, Bachireddy P
     GPR56 in GVL: marker or mechanism?
     Blood. 2024;143:1206-1207.
     PubMed    
     
     
     
225. MATHIOUDAKI A, Wang X, Sedloev D, Huth R, et al
     The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.
     Blood. 2024;143:1269-1281.
     PubMed     Abstract available
     
     
     
226. BAUMGARTNER F, Baer C, Bamopoulos S, Ayoub E, et al
     Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
     Blood. 2024;143:1139-1156.
     PubMed     Abstract available
     
     
     
227. KLEIN K, Kollmann S, Hiesinger A, List J, et al
     A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.
     Blood. 2024 Mar 18:blood.2023022655. doi: 10.1182/blood.2023022655.
     PubMed     Abstract available
     
     
     
228. AZOULAY E, Maertens J, Lemiale V
     How I manage acute respiratory failure in patients with hematological malignancies.
     Blood. 2024;143:971-982.
     PubMed     Abstract available
     
     
     
229. MACK EA, Dougher MC, Ginda AM, Cahill C, et al
     Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis.
     Blood. 2024;143:1049-1054.
     PubMed     Abstract available
     
     
     
230. FELIPE FUMERO E, Walter C, Frenz JM, Seifert FC, et al
     Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
     Blood. 2024 Mar 8:blood.2023021640. doi: 10.1182/blood.2023021640.
     PubMed     Abstract available
     
     
     
231. HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al
     MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
     Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184.
     PubMed     Abstract available
     
     
     
232. CHALANDON Y, Rousselot P, Chevret S, Cayuela JM, et al
     Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
     Blood. 2024 Mar 7:blood.2023023502. doi: 10.1182/blood.2023023502.
     PubMed     Abstract available
     
     
     
233. 
     Colom Diaz PA, Mistry JJ, Trowbridge JJ. Hematopoietic stem cell aging and leukemia transformation. Blood. 2023;142(6):533-542.
     Blood. 2024;143:939.
     PubMed    
     
     
     
234. AHMED R, Feldman AL
     Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
     Blood. 2024;143:938.
     PubMed    
     
     
     
235. O'CONNOR D, Valle-Inclan JE, Conde L, Bloye G, et al
     Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL.
     Blood. 2024;143:933-937.
     PubMed     Abstract available
     
     
     
236. ESCHERICH CS, Chen W, Li Y, Yang W, et al
     Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children.
     Blood. 2024 Mar 6:blood.2023023336. doi: 10.1182/blood.2023023336.
     PubMed     Abstract available
     
     
     
237. AVILA AVILA A, Nuantang K, Oliveira ML, Druillennec S, et al
     Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-Cell Acute Lymphoblastic Leukemia.
     Blood. 2024 Mar 4:blood.2023022455. doi: 10.1182/blood.2023022455.
     PubMed     Abstract available
     
     
     February 2024
238. BARROS PINTO MP, Cabecadas J
     Binucleated and cloverleaf-shaped nucleus in lymphocytes in CLL.
     Blood. 2024;143:833.
     PubMed    
     
     
     
239. MURTADHA M, Park M, Zhu Y, Caserta E, et al
     CD38-directed, single-chain T cell-engager targets leukemia stem cells through IFNgamma-induced CD38 expression.
     Blood. 2024 Feb 26:blood.2023021570. doi: 10.1182/blood.2023021570.
     PubMed     Abstract available
     
     
     
240. VAN OUTERSTERP I, Tasian SK, Reichert CE, Boeree A, et al
     Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain.
     Blood. 2024 Feb 23:blood.2023023120. doi: 10.1182/blood.2023023120.
     PubMed     Abstract available
     
     
     
241. BARBOSA K, Deshpande A, Perales M, Xiang P, et al
     Transcriptional control of leukemogenesis by the chromatin reader SGF29.
     Blood. 2024;143:697-712.
     PubMed     Abstract available
     
     
     
242. BISWAS J, Abdel-Wahab O
     A new SAGA for AML: targeting SGF29 in AML.
     Blood. 2024;143:657-658.
     PubMed    
     
     
     
243. SUMMERS RJ, Teachey DT, Hunger SP
     How I treat early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) in children.
     Blood. 2024 Feb 16:blood.2023023155. doi: 10.1182/blood.2023023155.
     PubMed     Abstract available
     
     
     
244. MENSURADO S, Condeco AC, Sanchez-Martinez D, Shirley S, et al
     CD155/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells.
     Blood. 2024 Feb 16:blood.2023022992. doi: 10.1182/blood.2023022992.
     PubMed     Abstract available
     
     
     
245. FISKUS W, Piel J, Collins MP, Hentemann M, et al
     BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
     Blood. 2024 Feb 16:blood.2023022832. doi: 10.1182/blood.2023022832.
     PubMed     Abstract available
     
     
     
246. COTY-FATTAL Z, Richardson AI
     A 3-year-old with chronic myeloid leukemia.
     Blood. 2024;143:651.
     PubMed    
     
     
     
247. BARAJAS JM, Rasouli M, Umeda M, Hiltenbrand R, et al
     Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors.
     Blood. 2024;143:619-630.
     PubMed     Abstract available
     
     
     
248. BERNT KM
     Menin dependence: UBTF-ITD AML joins the club.
     Blood. 2024;143:567-569.
     PubMed    
     
     
     
249. CHEN B, Abdel-Wahab O
     Targeting the cBAF complex in T-ALL.
     Blood. 2024;143:566-567.
     PubMed    
     
     
     
250. ARBER C
     Two to tango: engineered T cells against AML.
     Blood. 2024;143:476-478.
     PubMed    
     
     
     
251. QIU L, Naresh KN
     Mature plasmacytoid dendritic cell proliferation in association with mixed-phenotype acute leukemia, T/myeloid.
     Blood. 2024;143:561.
     PubMed    
     
     
     
252. DAO T, Xiong G, Mun SS, Meyerberg J, et al
     A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
     Blood. 2024;143:507-521.
     PubMed     Abstract available
     
     
     
253. BHATT VR, Uy GL, Klepin HD
     Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action.
     Blood. 2024;143:483-487.
     PubMed     Abstract available
     
     
     
254. ROUSSELOT P
     Old rivals become new friends.
     Blood. 2024;143:380-382.
     PubMed    
     
     
     
255. ORDONEZ MAZARIEGOS EE, Dimopoulos YP
     A rare case of ICUS progressing to MDS with isolated isochromosome 17q and AML.
     Blood. 2024;143:473.
     PubMed    
     
     
     January 2024
256. GU H, Chen C, Hou ZS, He XD, et al
     PI3Kgamma maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway.
     Blood. 2024 Jan 25:blood.2023022202. doi: 10.1182/blood.2023022202.
     PubMed     Abstract available
     
     
     
257. SCHRAW JM
     Anticancer drug exposure in utero and leukemia.
     Blood. 2024;143:293-294.
     PubMed    
     
     
     
258. BARATA JT
     Darwin, MSI2, and relapse in T-ALL.
     Blood. 2024;143:294-296.
     PubMed    
     
     
     
259. SAHASRABUDHE KD, Mims AS
     MRD in AML: who, what, when, where, and how?
     Blood. 2024;143:296-298.
     PubMed    
     
     
     
260. OTHMAN J, Tiong IS, O'Nions J, Dennis M, et al
     Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
     Blood. 2024;143:336-341.
     PubMed     Abstract available
     
     
     
261. LEUNG WK, Torres Chavez AG, French-Kim M, Shafer P, et al
     Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
     Blood. 2024 Jan 19:blood.2023021979. doi: 10.1182/blood.2023021979.
     PubMed     Abstract available
     
     
     
262. WEINACHT KG
     The rise of haplo: a quest for the perfect graft.
     Blood. 2024;143:193-195.
     PubMed    
     
     
     
263. 
     alphabetaT/CD19-depleted haploHSCT for pediatric leukemia.
     Blood. 2024;143:291.
     PubMed    
     
     
     
264. CHEN H, Wang H
     Acute myeloid leukemia with GATA2 and WT1 mutations mimicking acute promyelocytic leukemia.
     Blood. 2024;143:290.
     PubMed    
     
     
     
265. SAULTIER P, Michel G
     How I Treat: long-term survivors of childhood acute leukemia.
     Blood. 2024 Jan 16:blood.2023019804. doi: 10.1182/blood.2023019804.
     PubMed     Abstract available
     
     
     
266. BULDINI B, Varotto E, Maurer-Granofszky M, Gaipa G, et al
     CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.
     Blood. 2024 Jan 12:blood.2023021952. doi: 10.1182/blood.2023021952.
     PubMed     Abstract available
     
     
     
267. 
     Bamezai S, Pulikkottil AJ, Yadav T, et al. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood. 2023;142(1):90-105.
     Blood. 2024;143:184.
     PubMed    
     
     
     
268. DIMOPOULOS YP, Loghavi S
     Acute leukemia of ambiguous lineage with BCL11B rearrangement.
     Blood. 2024;143:183.
     PubMed    
     
     
     
269. GHORASHIAN S, Lucchini G, Richardson R, Nguyen K, et al
     CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
     Blood. 2024;143:118-123.
     PubMed     Abstract available
     
     
     
270. VELTMAAT L, Cortes J
     Arterio-Occlusive Events Among Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors.
     Blood. 2024 Jan 9:blood.2023022403. doi: 10.1182/blood.2023022403.
     PubMed     Abstract available
     
     
     
271. MOSS P
     Ibrutinib reversal of immune exhaustion in CLL.
     Blood. 2024;143:5-7.
     PubMed    
     
     
     
272. 
     Kennedy E, Coulter E, Halliwell E, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021;137(22):3064-3078.
     Blood. 2024;143:93.
     PubMed    
     
     
     
273. PAPAZOGLOU D, Wang XV, Shanafelt TD, Lesnick CE, et al
     Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.
     Blood. 2024;143:57-63.
     PubMed     Abstract available
     
     
     December 2023
274. QUESSADA J, Loosveld M
     CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia.
     Blood. 2023;142:2332.
     PubMed    
     
     
     
275. HASSERJIAN RP, Germing U, Malcovati L
     Diagnosis and classification of myelodysplastic syndromes.
     Blood. 2023;142:2247-2257.
     PubMed     Abstract available
     
     
     
276. DEZERN AE, Greenberg PL
     The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
     Blood. 2023;142:2258-2267.
     PubMed     Abstract available
     
     
     
277. CHIBA M, Shimono J, Suto K, Ishio T, et al
     Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
     Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423.
     PubMed     Abstract available
     
     
     
278. BRECCIA M
     A traffic light for TFR by lineage-specific MRD.
     Blood. 2023;142:2129-2130.
     PubMed    
     
     
     
279. FU L, Gong S
     KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
     Blood. 2023;142:2220.
     PubMed    
     
     
     
280. 
     NIH natural history study of FPDMM patients.
     Blood. 2023;142:2222.
     PubMed    
     
     
     
281. FRANK D, Patnana PK, Vorwerk J, Mao L, et al
     Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
     Blood. 2023;142:2175-2191.
     PubMed     Abstract available
     
     
     
282. CUNNINGHAM L, Merguerian M, Calvo KR, Davis J, et al
     Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
     Blood. 2023;142:2146-2158.
     PubMed     Abstract available
     
     
     
283. MARCELLINO BK
     PPM1D inhibition may allow us to WIP leukemia.
     Blood. 2023;142:2040-2042.
     PubMed    
     
     
     
284. COUSTAN-SMITH E, Conter V
     Closing the circle for ETP ALL.
     Blood. 2023;142:2039-2040.
     PubMed    
     
     
     
285. WOOD BL, Devidas M, Summers RJ, Chen Z, et al
     Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.
     Blood. 2023;142:2069-2078.
     PubMed     Abstract available
     
     
     
286. DIMITRIOU M, Mortera-Blanco T, Tobiasson M, Mazzi S, et al
     Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation.
     Blood. 2023 Dec 14:blood.2023022851. doi: 10.1182/blood.2023022851.
     PubMed     Abstract available
     
     
     
287. PALM-APERGI C
     PLK4, a potential target against AML.
     Blood. 2023;142:1941-1942.
     PubMed    
     
     
     
288. STONE RM
     FLT(3)-ing about: the search for the best inhibitor.
     Blood. 2023;142:1937-1938.
     PubMed    
     
     
     
289. MAN CH, Lam W, Dang CC, Zeng XY, et al
     Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
     Blood. 2023;142:2002-2015.
     PubMed     Abstract available
     
     
     
290. FLEMING S, Tsai XC, Morris R, Hou HA, et al
     TP53 status and impact on AML prognosis within the ELN 2022 risk classification.
     Blood. 2023;142:2029-2033.
     PubMed     Abstract available
     
     
     
291. LOO S, Roberts AW, Anstee NS, Kennedy GA, et al
     Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
     Blood. 2023;142:1960-1971.
     PubMed     Abstract available
     
     
     November 2023
292. BEWERSDORF JP, How J, Masarova L, Bose P, et al
     Moving toward disease modification in polycythemia vera.
     Blood. 2023;142:1859-1870.
     PubMed     Abstract available
     
     
     
293. DAVIDS MS
     Functional cure reported in CLL.
     Blood. 2023;142:1761-1763.
     PubMed    
     
     
     
294. LIN E, Chen W
     Acute myeloid leukemia with NUP98::HOXA9 mimicking acute promyelocytic leukemia.
     Blood. 2023;142:1845.
     PubMed    
     
     
     
295. 
     Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022;140(25):2754-2756.
     Blood. 2023;142:1846-1847.
     PubMed    
     
     
     
296. THOMPSON PA, Bazinet A, Wierda WG, Tam CS, et al
     Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
     Blood. 2023;142:1784-1788.
     PubMed     Abstract available
     
     
     
297. KIM R, Bergugnat H, Pastoret C, Pasquier F, et al
     Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
     Blood. 2023;142:1806-1817.
     PubMed     Abstract available
     
     
     
298. ROLLIG C
     Gemtuzumab ozogamicin in AML: the next chapter.
     Blood. 2023;142:1673-1674.
     PubMed    
     
     
     
299. STRASSER B, Haushofer A
     Cabot rings in chronic myelomonocytic leukemia.
     Blood. 2023;142:1757.
     PubMed    
     
     
     
300. FREEMAN SD, Thomas A, Thomas I, Hills RK, et al
     Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
     Blood. 2023;142:1697-1707.
     PubMed     Abstract available
     
     
     
301. 
     Fractionated vs single-dose gemtuzumab for AML.
     Blood. 2023;142:1759.
     PubMed    
     
     
     
302. BUENO C, Torres-Ruiz R, Velasco-Hernandez T, Molina O, et al
     A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.
     Blood. 2023;142:1752-1756.
     PubMed     Abstract available
     
     
     
303. THOL FR, Dohner H, Ganser A
     How I treat refractory and relapsed acute myeloid leukemia.
     Blood. 2023 Nov 9:blood.2023022481. doi: 10.1182/blood.2023022481.
     PubMed     Abstract available
     
     
     
304. VYAS P
     Changing treatment changing prognosis of mutations.
     Blood. 2023;142:1583-1585.
     PubMed    
     
     
     
305. AOKI K, Hyuga M, Tarumoto Y, Nishibuchi G, et al
     Canonical BAF complex regulates the oncogenic program in human T-cell acute lymphoblastic leukemia.
     Blood. 2023 Nov 3:blood.2023020857. doi: 10.1182/blood.2023020857.
     PubMed     Abstract available
     
     
     October 2023
306. JABBOUR EJ, Haddad FG, Short NJ, Senapati J, et al
     Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission.
     Blood. 2023 Oct 25:blood.2023022330. doi: 10.1182/blood.2023022330.
     PubMed     Abstract available
     
     
     
307. MALAGA ML, Carrillo LF
     FISH-negative, karyotype-negative acute promyelocytic leukemia.
     Blood. 2023;142:1328.
     PubMed    
     
     
     
308. PRINCE HM
     Blocked addiction to IL-15 for treating T-LGLL.
     Blood. 2023;142:1258-1260.
     PubMed    
     
     
     
309. XIE J, Bao X, Xue SL, Shen H, et al
     Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML.
     Blood. 2023;142:1323-1327.
     PubMed    
     
     
     
310. ZHANG J, Duan Y, Wu P, Chang Y, et al
     Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-resistance in T-cell Acute Lymphoblastic Leukemia.
     Blood. 2023 Oct 6:blood.2023020490. doi: 10.1182/blood.2023020490.
     PubMed     Abstract available
     
     
     
311. KUMAR J, Petrova-Drus K
     Acute leukemia with predominantly myeloid differentiation and TBL1XR1::CSF1R fusion.
     Blood. 2023;142:1253.
     PubMed    
     
     
     
312. CHELOOR KOVILAKAM S, Gu M, Dunn WG, Marando L, et al
     Prevalence and significance of DDX41 gene variants in the general population.
     Blood. 2023;142:1185-1192.
     PubMed     Abstract available
     
     
     
313. YAMAMOTO S, Sanefuji M, Suzuki M, Sonoda Y, et al
     Pediatric leukemia and maternal occupational exposure to anticancer drugs: The Japan Environment and Children's Study.
     Blood. 2023 Oct 3:blood.2023021008. doi: 10.1182/blood.2023021008.
     PubMed     Abstract available
     
     
     September 2023
314. GOEDE V
     Frailty is also a target for targeted drugs in CLL.
     Blood. 2023;142:1107-1108.
     PubMed    
     
     
     
315. VAN DER STRATEN L, Stege CAM, Kersting S, Nasserinejad K, et al
     Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
     Blood. 2023;142:1131-1142.
     PubMed     Abstract available
     
     
     
316. MERLI P, Algeri M, Galaverna F, Bertaina V, et al
     TCRalphabeta/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis.
     Blood. 2023 Sep 22:blood.2023021336. doi: 10.1182/blood.2023021336.
     PubMed     Abstract available
     
     
     
317. LI S, Adams PD
     Targeting the epichaperome to combat AML.
     Blood. 2023;142:1031-1032.
     PubMed    
     
     
     
318. 
     Gribben JG. Targeting the methylome to improve CLL outcome. Blood. 2023;142(1):4-6.
     Blood. 2023;142:1103.
     PubMed    
     
     
     
319. CARTER BZ, Mak PY, Muftuoglu M, Tao W, et al
     Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
     Blood. 2023;142:1056-1070.
     PubMed     Abstract available
     
     
     
320. UCKELMANN HJ, Klusmann JH
     Double trouble: IRAK1/4 inhibitors in AML/MDS.
     Blood. 2023;142:945-946.
     PubMed    
     
     
     
321. KWOK M, Stankovic T
     CLL patients: GIVe me three!
     Blood. 2023;142:941-943.
     PubMed    
     
     
     
322. HUBER H, Tausch E, Schneider C, Edenhofer S, et al
     Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
     Blood. 2023;142:961-972.
     PubMed     Abstract available
     
     
     
323. BENNETT J, Ishikawa C, Agarwal P, Yeung J, et al
     Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
     Blood. 2023;142:989-1007.
     PubMed     Abstract available
     
     
     
324. FEI MY, Wang Y, Chang BH, Xue K, et al
     The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment.
     Blood. 2023;142:903-917.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.